Notably, we identified that disease severity and NF2 pathogenic variants did not appear to have any significant influence on the TME, whilst bevacizumab-treatment was associated with a significant increase in CD44+ Schwann cells, suggesting a potential increase in matrix remodelling within these tumours. Here, CD44 is linked to neoplasm.